Pursuing therapeutic targetsVON HOFF, Daniel D; GRAY, Phillip J; DRAGOVICH, Tomislav et al.Seminars in oncology. 2006, Vol 33, Num 4, issn 0093-7754, 156 p.Serial Issue

Tubulin-associated drug targets : Aurora kinases, polo-like kinases, and othersWARNER, Steven L; GRAY, Phillip J; VON HOFF, Daniel D et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 436-448, issn 0093-7754, 13 p.Article

Patient-Reported Outcomes After 3-Dimensional Conformal, Intensity-Modulated, or Proton Beam Radiotherapy for Localized Prostate CancerGRAY, Phillip J; PALY, Jonathan J; HAHN, Stephen M et al.Cancer. 2013, Vol 119, Num 9, pp 1729-1735, issn 0008-543X, 7 p.Article

Targeting Cdc37 Inhibits Multiple Signaling Pathways and Induces Growth Arrest in Prostate Cancer CellsGRAY, Phillip J; STEVENSON, Mary Ann; CALDERWOOD, Stuart K et al.Cancer research (Baltimore). 2007, Vol 67, Num 24, pp 11942-11950, issn 0008-5472, 9 p.Article

Targeting the Bcl-2 family in cancer therapyPAPADOPOULOS, Kyriakos.Seminars in oncology. 2006, Vol 33, Num 4, pp 449-456, issn 0093-7754, 8 p.Article

Role of raf kinase in cancer : Therapeutic potential of targeting the raf/MEK/ERK signal transduction pathwayGOLLOB, Jared A; WILHELM, Scott; CARTER, Chris et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 392-406, issn 0093-7754, 15 p.Article

Epidermal growth factor receptor targeting in cancerMENDELSOHN, John; BASELGA, Jose.Seminars in oncology. 2006, Vol 33, Num 4, pp 369-385, issn 0093-7754, 17 p.Article

Heat shock protein 90 : A unique chemotherapeutic targetCULLINAN, Sara B; WHITESELL, Luke.Seminars in oncology. 2006, Vol 33, Num 4, pp 457-465, issn 0093-7754, 9 p.Article

Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data BaseGRAY, Phillip J; FEDEWA, Stacey A; SHIPLEY, William U et al.European urology. 2013, Vol 63, Num 5, pp 823-829, issn 0302-2838, 7 p.Article

New paradigms in anticancer therapy : Targeting multiple signaling pathways with kinase inhibitorsFAIVRE, Sandrine; DJELLOUL, Siham; RAYMOND, Eric et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 407-420, issn 0093-7754, 14 p.Article

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agentsHONG WANG; HAIYONG HAN; MOUSSES, Spyro et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 513-520, issn 0093-7754, 8 p.Article

Targeting HER2 epitopesSUMANTA KUMAR PAL; PEGRAM, Mark.Seminars in oncology. 2006, Vol 33, Num 4, pp 386-391, issn 0093-7754, 6 p.Article

The hypoxic inducible stress response as a target for cancer drug discoveryWELSH, Sarah J; MEI YEE KOH; POWIS, Garth et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 486-497, issn 0093-7754, 12 p.Article

Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer elementHURLEY, Laurence H; VON HOFF, Daniel D; SIDDIQUI-JAIN, Adam et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 498-512, issn 0093-7754, 15 p.Article

Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survivalGRAY, Phillip J; MAK, Raymond H; KOZONO, David E et al.Lung cancer. 2014, Vol 85, Num 2, pp 239-244, issn 0169-5002, 6 p.Article

Novel agents that target tublin and related elementsROWINSKY, Eric K; CALVO, Emiliano.Seminars in oncology. 2006, Vol 33, Num 4, pp 421-435, issn 0093-7754, 15 p.Article

Preclinical and clinical development of novel agents that target the protein kinase C familySEROVA, Maria; GHOUL, Aïda; BENHADJI, Karim A et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 466-478, issn 0093-7754, 13 p.Article

Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acidHUANG, Ru Chih C; CHIH CHUAN CHANG; MOLD, David et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 479-485, issn 0093-7754, 7 p.Article